Q1 Earnings Forecast for NeoGenomics Issued By William Blair

NeoGenomics, Inc. (NASDAQ:NEO) – Analysts at William Blair issued their Q1 2026 earnings per share estimates for shares of NeoGenomics in a research note issued to investors on Tuesday, February 18th. William Blair analyst A. Brackmann anticipates that the medical research company will earn $0.00 per share for the quarter. The consensus estimate for NeoGenomics’ current full-year earnings is ($0.05) per share. William Blair also issued estimates for NeoGenomics’ Q2 2026 earnings at $0.01 EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at $0.03 EPS.

NeoGenomics (NASDAQ:NEO) last posted its quarterly earnings data on Tuesday, February 18th. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.05). NeoGenomics had a negative return on equity of 2.10% and a negative net margin of 11.92%. The firm had revenue of $172.00 million during the quarter, compared to analysts’ expectations of $173.40 million.

Other equities research analysts have also recently issued reports about the company. Bank of America dropped their target price on NeoGenomics from $19.00 to $16.00 and set a “neutral” rating for the company in a report on Wednesday. Needham & Company LLC dropped their target price on NeoGenomics from $19.00 to $18.00 and set a “buy” rating for the company in a report on Wednesday. The Goldman Sachs Group dropped their target price on NeoGenomics from $20.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Jefferies Financial Group began coverage on NeoGenomics in a report on Tuesday, December 10th. They set a “buy” rating and a $22.00 target price for the company. Finally, Benchmark cut NeoGenomics from a “buy” rating to a “hold” rating in a report on Monday, January 13th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.80.

NeoGenomics Price Performance

NEO opened at $11.86 on Friday. The stock has a market capitalization of $1.52 billion, a P/E ratio of -19.13 and a beta of 1.23. NeoGenomics has a 12-month low of $10.69 and a 12-month high of $19.11. The stock has a 50-day moving average price of $15.28 and a 200-day moving average price of $15.49. The company has a current ratio of 1.98, a quick ratio of 1.91 and a debt-to-equity ratio of 0.38.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in NEO. Creative Planning increased its position in NeoGenomics by 42.3% during the 3rd quarter. Creative Planning now owns 23,547 shares of the medical research company’s stock valued at $347,000 after buying an additional 7,004 shares in the last quarter. Blue Trust Inc. increased its position in NeoGenomics by 42.3% during the 3rd quarter. Blue Trust Inc. now owns 3,318 shares of the medical research company’s stock valued at $46,000 after buying an additional 987 shares in the last quarter. Nisa Investment Advisors LLC increased its position in NeoGenomics by 5.0% during the 3rd quarter. Nisa Investment Advisors LLC now owns 45,104 shares of the medical research company’s stock valued at $665,000 after buying an additional 2,166 shares in the last quarter. Fernwood Investment Management LLC increased its position in NeoGenomics by 1.0% during the 3rd quarter. Fernwood Investment Management LLC now owns 89,500 shares of the medical research company’s stock valued at $1,320,000 after buying an additional 900 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new position in NeoGenomics during the 3rd quarter valued at approximately $1,101,000. Institutional investors own 98.50% of the company’s stock.

NeoGenomics Company Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.